Ajanta Pharma has reported a robust performance for the quarter and year ended March 31, 2026. The company achieved a 21% increase in quarterly revenue from operations, reaching Rs. 1,422 crore, while profit after tax grew by 18% to Rs. 267 crore. Driven by strong branded generic sales across key global markets and consistent growth in US generics, the company demonstrates a healthy upward trajectory in its financial results.
Quarterly Financial Highlights
For the fourth quarter ended March 31, 2026, Ajanta Pharma delivered impressive results despite challenging conditions. Revenue from operations surged to Rs. 1,422 crore compared to Rs. 1,170 crore in the same period last year, marking a 21% growth. EBITDA stood at Rs. 333 crore, and when excluding forex impacts, it reached Rs. 375 crore, reflecting a strong 26% growth. Profit after tax reached Rs. 267 crore, up 18% from the previous year.
Annual Performance Summary
For the full financial year 2026, the company recorded revenue from operations of Rs. 5,453 crore, representing a 17% increase over FY 2025. Profit after tax for the year grew to Rs. 1,056 crore, a 15% increase compared to the previous year. The company maintained strong operational efficiency with an ROCE of 33% and RONW of 25%.
Segment-Wise Performance
The company’s performance was bolstered by a diversified international and domestic presence. Branded Generics in India showed a 14% growth for the year, while US Generics experienced significant momentum with a 49% increase, reaching Rs. 1,557 crore in revenue for the full year. The company continues to demonstrate leadership in sub-therapeutic segments, with over 50% of its products categorized as 1st to market.
Research and Development Focus
Ajanta Pharma continues to invest heavily in innovation, with R&D expenses totaling Rs. 252 crore for FY 2026, maintaining a 5% revenue allocation. The company has a robust pipeline with 49 commercialized ANDAs and 19 awaiting approval by the US FDA, underscoring its commitment to future growth through R&D excellence.
Source: BSE
